Các thuốc chẹn thụ thể angiotensin phổ biến có thể điều chỉnh trực tiếp hệ thống miễn dịch qua VDR, PPAR và CCR2b

Mann DL, Deswal A: Angiotensin-receptor blockade in acute myocardial infarction – a matter of dose. N Engl J Med. 349 (20): 1963-5. 10.1056/NEJMe038163. 2003 Nov 13

United States Food and Drug Administration: Approval Package for NDA21-286. Pharmacology Review, figures 1.1.1.1,1.1.1.3 and1.1.1.4, http://www.fda.gov/cder/foi/nda/2002/21-286_Benicar_pharmr_P1.pdf

Izuhara Y, Nangaku M, Inagi R, Tominaga N, Aizawa T, Kurokawa K, van Ypersele de Strihou C, Miyata T: Renoprotective Properties of Angiotensin Receptor Blockers beyond Blood Pressure Lowering. J Am Soc Nephrol. 2005, 16 (12): 3631-41. 10.1681/ASN.2005050522.

Lewis EJ, Lewis JB: Treatment of diabetic nephropathy with angiotensin II receptor antagonist. Clin Exp Nephrol. 2003, 7 (1): 1-8. 10.1007/s101570300000.

Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001, 345: 861-869. 10.1056/NEJMoa011161.

Viberti GC, Wheeldon MN: Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: A blood pressure-independent effect. Circulation. 2002, 106: 672-678. 10.1161/01.CIR.0000024416.33113.0A.

Schieffer B, Bunte C, Witte J, Hoeper K, Boger RH, Schwedhelm E, Drexler H: Comparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease. J Am Coll Cardiol. 44 (2): 362-8. 10.1016/j.jacc.2004.03.065. 2004 Jul 21

Luno J, Praga M, de Vinuesa SG: The reno-protective effect of the dual blockade of the renin angiotensin system (RAS). Curr Pharm Des. 2005, 11 (10): 1291-300. 10.2174/1381612053507413.

Waterhouse JC, Marshall TG, Fenter B, Mangin M, Blaney G: High levels of active 1,25-dihydroxyvitamin D despite low levels of the 25-hydroxyvitamin D precursor - Implications of dysregulated vitamin D for disgnosis and treatment of Chronic Disease. Vitamin D: New Research. Edited by: Stoltz VD. 2006, New York: Nova Science Publishers, 1:

Marshall TG, Marshall FE: Sarcoidosis succumbs to antibiotics – implications for autoimmune disease. Autoimmun Rev. 2004, 3 (4): 295-300. 10.1016/j.autrev.2003.10.001.

Raz E, Tighe H, Sato Y, Corr M, Dudler JA, Roman M, Swain SL, Spiegelberg HL, Carson DA: Preferential induction of a Th1 immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization. Proc Natl Acad Sci USA. 93 (10): 5141-5145. 10.1073/pnas.93.10.5141. 1996 May 14

Cantorna MT, Zhu Y, Froicu M, Wittke A: Vitamin D status, 1,25-dihydroxyvitamin D3, and the immune system. Am J Clin Nutr. 2004, 80 (6 Suppl): 1717S-20S.

Mallat Z, Ait-Oufella H, Tedgui A: Regulatory T cell responses: potential role in the control of atherosclerosis. Curr Opin Lipidol. 2005, 16 (5): 518-24. 10.1097/01.mol.0000182532.11512.90.

Yoon JW, Jun HS: Autoimmune destruction of pancreatic Beta cells. Am J Ther. 2005, 12 (6): 580-91. 10.1097/01.mjt.0000178767.67857.63.

Wittke A, Weaver V, Mahon BD, August A, Cantorna MT: Vitamin D receptor-deficient mice fail to develop experimental allergic asthma. J Immunol. 173 (5): 3432-6. 2004 Sep 1

Dusso AS, Kamimura S, Gallieni M, Zhong M, Negrea L, Shapiro S, Slatopolsky E: gamma-Interferon-induced resistance to 1,25-(OH)2 D3 in human monocytes and macrophages: a mechanism for the hypercalcemia of various granulomatoses. J Clin Endocrinol Metab. 1997, 82 (7): 2222-32. 10.1210/jc.82.7.2222.

Potashnik G, Lunenfeld E, Levitas E, Itskovitz J, Albutiano S, Yankowitz N, Sonin Y, Levy J, Glezerman M, Shany S: The relationship between endogenous oestradiol and vitamin D3 metabolites in serum and follicular fluid during ovarian stimulation for in-vitro fertilization and embryo transfer. Hum Reprod. 1992, 7 (10): 1357-60.

Chatterjee M: Vitamin D and genomic stability. Mutat Res. 475 (1–2): 69-87. 2001 Apr 18

Nagpal S, Na S, Rathnachalam R: Noncalcemic actions of vitamin D receptor ligands. Endocr Rev. 2005, 26 (5): 662-87. 10.1210/er.2004-0002.

Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M, Qi N, Wang J, Avery MA, Kurtz TW: Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension. 2004, 43 (5): 993-1002. 10.1161/01.HYP.0000123072.34629.57.

Cabrero A, Laguna JC, Vazquez M: Peroxisome proliferator-activated receptors and the control of inflammation. Curr Drug Targets Inflamm Allergy. 2002, 1: 243-8. 10.2174/1568010023344616.

Genolet R, Wahli W, Michalik L: PPARs as drug targets to modulate inflammatory responses?. Curr Drug Targets Inflamm Allergy. 2004, 3 (4): 361-75. 10.2174/1568010042634578.

Preobrazhensky AA, Dragan S, Kawano T, Gavrilin MA, Gulina IV, Chakravarty L, Kolattukudy PE: Monocyte chemotactic protein-1 receptor CCR2B is a glycoprotein that has tyrosine sulfation in a conserved extracellular N-terminal region. J Immunol. 165 (9): 5295-303. 2000 Nov 1

Tanaka S, Green SR, Quehenberger O: Differential expression of the isoforms for the monocyte chemoattractant protein-1 receptor, CCR2, in monocytes. Biochem Biophys Res Commun. 290 (1): 73-80. 10.1006/bbrc.2001.6149. 2002 Jan 11

Casey PJ, Gilman AG: G protein involvement in receptor-effector coupling. J Biol Chem. 263 (6): 2577-80. 1988 Feb 25

AutoDock, Automatic Docking of Flexible Ligands to Macromolecules.http://www.scripps.edu/mb/olson/doc/autodock/

Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, Belew RK, Olson AJ: Automated docking using Lamarckian genetic algorithm and an empirical binding free energy function. J Comp Chem. 19: 1639-1662. 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B.

Osterberg F, Morris GM, Sanner MF, Olson AJ, Goodsell DS: Automated docking to multiple target structures: incorporation of protein mobility and structural water heterogeneity in AutoDock. Proteins. 46 (1): 34-40. 10.1002/prot.10028. 2002 Jan 1

Toprakci M, Yelekci K: Docking studies on monoamine oxidase-B inhibitors: estimation of inhibition constants (K(i)) of a series of experimentally tested compounds. Bioorg Med Chem Lett. 15 (20): 4438-46. 10.1016/j.bmcl.2005.07.043. 2005 Oct 15

Chen K, Adelstein SJ, Kassis AI: Molecular simulation of ligand-binding with DNA: implications for 125I-labeled pharmaceutical design. Int J Radiat Biol. 2004, 80 (11–12): 921-6.

Xu HE, Lambert MH, Montana VG, Plunket KD, Moore LB, Collins JL, Oplinger JA, Kliewer SA, Gampe RT, McKee DD, Moore JT, Willson TM: Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors. Proc Natl Acad Sci U S A. 98 (24): 13919-24. 10.1073/pnas.241410198. 2001 Nov 20

Rochel N, Wurtz JM, Mitschler A, Klaholz B, Moras D: The crystal structure of the nuclear receptor for vitamin D bound to its natural ligand. Mol Cell. 2000, 5 (1): 173-9. 10.1016/S1097-2765(00)80413-X.

Eelen G, Verlinden L, Rochel N, Claessens F, De Clercq P, Vandewalle M, Tocchini-Valentini G, Moras D, Bouillon R, Verstuyf A: Superagonistic action of 14-epi-analogs of 1,25-dihydroxyvitamin D explained by vitamin D receptor-coactivator interaction. Mol Pharmacol. 2005, 67 (5): 1566-73. 10.1124/mol.104.008730.

Scripps Research Institute, Molecular Graphics Laboratory, MGLtools. http://www.scripps.edu/~sanner/software/

The Python Molecular Viewer. http://www.pymol.org

Strader CD, Fong TM, Graziano MP, Tota MR: The family of G-protein-coupled receptors. FASEB J. 1995, 9 (9): 745-54.

Shi XF, Liu S, Xiangyu J, Zhang Y, Huang J, Liu S, Liu CQ: Structural analysis of human CCR2b and primate CCR2b by molecular modeling and molecular dynamics simulation. J Mol Model (Online). 2002, 8 (7): 217-22. 10.1007/s00894-002-0089-6.

Pappu RV, Marshall GR, Ponder JW: A potential smoothing algorithm accurately predicts transmembrane helix packing. Nat Struct Biol. 1999, 6 (1): 50-5. 10.1038/4922.

TINKER – Software tools for molecular design. http://dasher.wustl.edu/tinker

Sali A, Blundell TL: Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol. 234 (3): 779-815. 10.1006/jmbi.1993.1626. 1993 Dec 5

MODELLER Program for comparative protein structure modelling by satisfaction of spatial restraints. http://salilab.org/modeller/modeller.html

Baba M, Nishimura O, Kanzaki N, Okamoto M, Sawada H, Iizawa Y, Shiraishi M, Aramaki Y, Okonogi K, Ogawa Y, Meguro K, Fujino M: A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc Natl Acad Sci USA. 96 (10): 5698-5703. 10.1073/pnas.96.10.5698. 1999 May 11

Martin SS, Boucard AA, Clement M, Escher E, Leduc R, Guillemette G: Analysis of the third transmembrane domain of the human type 1 angiotensin II receptor by cysteine scanning mutagenesis. J Biol Chem. 279 (49): 51415-23. 10.1074/jbc.M407965200. 2004 Dec 3

Goodsell DS, Olson AJ: Automated Docking of Substrates to Proteins by Simulated Annealing. Proteins. 1990, 8 (3): 195-202. 10.1002/prot.340080302.

Morris GM, Goodsell DS, Huey R, Olson AJ: Distributed Automated Docking of Flexible Ligands to Proteins: Parallel Applications of AutoDock 2.4. J Comput Aided Mol Des. 1996, 10 (4): 293-304. 10.1007/BF00124499.

Omdahl JL, Morris HA, May BK: Hydroxylase enzymes of the vitamin D pathway: expression, function, and regulation. Annu Rev Nutr. 2002, 22: 139-66. 10.1146/annurev.nutr.22.120501.150216.

Wang J, Cieplak P, Kollman PA: How Well Does a Restrained Electrostatic Potential (RESP) Model Perform in Calcluating Conformational Energies of Organic and Biological Molecules?. J Comput Chem. 2000, 21: 1049-1074. 10.1002/1096-987X(200009)21:12<1049::AID-JCC3>3.0.CO;2-F.

Akira Dobashi's: 3D Pharmaceutical Structure Database. Tokyo University of Pharmacy and Life Sciences, http://www.pharmis.org/3dpsd/index.htm

Ghemical molecular modelling package. http://www.bioinformatics.org/ghemical/

Blair JD: SAMBA: Integrating UNIX and Windows. 1998, Seattle: SSC Publishing, ISBN: 1-57831-006-7

Acevedo A, Stoynova L, Davis K, Solorzano R, Collins ED: Role of residues 143 and 278 of the human nuclear Vitamin D receptor in the full-length and Delta165-215 deletion mutant. J Steroid Biochem Mol Biol. 2004, 89–90 (1–5): 83-7. 10.1016/j.jsbmb.2004.03.051.

Tsukahara T, Tsukahara R, Yasuda S, Makarova N, Valentine WJ, Allison P, Yuan H, Baker DL, Li Z, Bittman R, Parrill A, Tigyi G: Different residues mediate recognition of 1-O-oleyl-lysophosphatidic acid and rosiglitazone in the ligand binding domain of PPAR1. J Biol Chem. 2005 Dec 1.

Wallace AC, Laskowski RA, Thornton JM: A program to generate schematic diagrams of protein-ligand interactions. Protein Eng. 1995, 8 (2): 127-34.

LIGPLOT-Program for automatically plotting protein-ligand interactions. http://www.biochem.ucl.ac.uk/bsm/ligplot/ligplot.html

McDonald IK, Thornton JM: Satisfying Hydrogen Bonding Potential in Proteins. J Mol Biol. 238 (5): 777-93. 10.1006/jmbi.1994.1334. 1994 May 20

HBPLUS-Hydrogen Bond Calculation Program. http://www.biochem.ucl.ac.uk/bsm/hbplus/home.html

Shaffer PL, McDonnell DP, Gewirth DT: Characterization of transcriptional activation and DNA-binding functions in the hinge region of the vitamin D receptor. Biochemistry. 44 (7): 2678-85. 10.1021/bi0477182. 2005 Feb 22